Search
Search Results
##search.searchResults.foundPlural##
-
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
4021PDF: 1790HTML: 11976Figures Haase: 307 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2733PDF: 1267HTML: 178 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3938PDF: 1392HTML: 2201Fig.1: 300Fig. 2: 286 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
2091PDF: 1137HTML: 273 -
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
3026PDF: 1259HTML: 11439 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
2145PDF: 900HTML: 273 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2449PDF: 1140HTML: 2041Characteristic of study group: 263 -
-
PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome
1373PDF: 869HTML: 430 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2267PDF: 1404HTML: 3527 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2752PDF: 892HTML: 5404 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1654PDF: 1037HTML: 272 -
APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA
1772PDF: 711HTML: 2457 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3082PDF: 1366HTML: 2853Figure 1: 227 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
801PDF: 510HTML: 6296 -
-
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2882PDF: 1026HTML: 611 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1263PDF: 596HTML: 404 -
PERIOPERATIVE MANAGEMENT OF SICKLE CELL DISEASE: A NARRATIVE REVIEW
10816PDF: 3400HTML: 1676 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4173PDF: 1234HTML: 482 -
NEW STRATEGIES FOR STEM CELL MOBILIZATION
2639PDF: 987HTML: 2586 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1944PDF: 973HTML: 1574 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4723PDF: 1594HTML: 8562 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
2224HTML: 1777PDF: 1226 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3349PDF: 1711HTML: 410 -
The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study
2714PDF: 1040HTML: 398 -
MIR-140 TARGETS LNCRNA DNAJC3-AS1 TO SUPPRESS CELL PROLIFERATION IN ACUTE MYELOID LEUKEMIA AML proliferation and MIR-140 LNCRNA DNAJC3-AS1 target.
1362PDF: 689HTML: 332 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1896PDF: 1444HTML: 673 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2972PDF: 1272HTML: 3334







